S. Verma

S. Verma, R. Chow, H. Lam, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

In Reply

S. Verma, 2017, The oncologist.

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.

J. Baselga, K. Blackwell, S. Verma, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P1.15-007 Randomized Phase III Trial of Enoxaparin in Addition to Standard Treatment in Small Cell Lung Cancer: The RASTEN Trial

L. Ek, S. Verma, P. Bendahl, 2017 .

Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women

S. Verma, M. Clemons, O. Freedman, 2006, Breast Cancer Research and Treatment.

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study

L. Fallowfield, S. Verma, X. Pivot, 2016 .

Models of care for early-stage breast cancer in Canada.

S. Verma, L. Sidéris, A. Joy, 2011, Current oncology.

What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?

J. Mackey, S. Verma, G. Dranitsaris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?

Hans T. Chung, Liying Zhang, I. Poon, 2018, Lung cancer.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Min Hwan Kim, Sung-Bae Kim, Chiun-Sheng Huang, 2022, The New England journal of medicine.

First-Line Trials of HER-2-Directed Therapy for HER-2-Positive ABC Chemotherapy Companions

S. Verma, D. Rayson, A. Joy, 2013 .

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.

L. Fallowfield, G. Curigliano, S. Verma, 2017, Breast.

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer

S. Verma, N. Hauser, X. Pivot, 2016, Cancer medicine.

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

P. Gascón, S. Verma, G. Dranitsaris, 2007, Supportive Care in Cancer.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

E. Winer, G. Hortobagyi, K. Blackwell, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

E. Winer, G. Hortobagyi, K. Blackwell, 2016, The New England journal of medicine.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

S. Loi, H. Iwata, S. Loibl, 2015, The New England journal of medicine.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

S. Loi, H. Rugo, H. Iwata, 2016, The oncologist.

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease

S. Verma, A. Matutino, C. Amaro, 2018, Therapeutic advances in medical oncology.

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

G. Curigliano, S. Verma, S. Im, 2021, Annals of Oncology.

The impact of Angelina Jolie's (AJ) story on genetic referral and testing at an academic cancer centre.

S. Verma, A. Eisen, Paul Hewitt, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Reflex EGFR/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

S. Verma, S. Cheng, P. Cheema, 2017, Journal of oncology practice.

Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System

S. Verma, P. Ellis, N. Leighl, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting triple-negative breast cancer: optimising therapeutic outcomes.

K. Gelmon, J. Mackey, S. Verma, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary care physicians' views of routine follow-up care of cancer survivors.

S. Verma, B. Harvey, E. Grunfeld, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

S. Verma, G. Dranitsaris, M. Clemons, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.

S. Verma, R. Dent, L. Provencher, 2011, Current oncology.

Platinum-based chemotherapy in triple-negative advanced breast cancer

A. Kiss, Jeff Myers, S. Verma, 2014, Breast Cancer Research and Treatment.

Quality of life (QOL) and symptom burden (SB) in patients with breast cancer

Liying Zhang, S. Verma, E. Rakovitch, 2017, Supportive Care in Cancer.

Antiangiogenic Therapy in Advanced Non–small‐cell Lung Cancer: A Meta‐analysis of Phase III Randomized Trials

Kelvin K. W. Chan, R. Kerbel, S. Verma, 2017, Clinical lung cancer.

Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study.

S. Verma, D. Miles, X. Pivot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer.

S. Verma, N. Leighl, S. Hogeveen, 2011, The oncologist.

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.

K. Gelmon, J. Mackey, R. Kerbel, 2012, Cancer treatment reviews.

Approach to biomarker testing: perspectives from various specialties.

S. Verma, P. Ellis, N. Leighl, 2016, Current oncology.

Canadian supportive care recommendations for the management of neutropenia in patients with cancer

S. Verma, S. Chia, J. Mikhael, 2007, Current oncology.

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

M. Dowsett, S. Loi, H. Iwata, 2017, The oncologist.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.

A. Rossi, S. Verma, G. Tonini, 2008, Expert opinion on biological therapy.

Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?

S. Verma, M. Clemons, O. Freedman, 2005, Cancer treatment reviews.

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.

S. Loi, H. Iwata, S. Loibl, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review of the clinical studies using the 21-gene assay.

S. Verma, E. Warner, K. Pritchard, 2010, The oncologist.

Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.

S. Verma, E. Warner, A. Eisen, 2018, The oncologist.

Advances in the management of metastatic breast cancer : options beyond first-line chemotherapy

S. Verma, J. Ayoub, S. Verma, 2012 .

Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach

S. Verma, D. Landaverde, 2012 .

Targeting triple-negative breast cancer: optimising therapeutic outcomes.

K. Gelmon, J. Mackey, S. Verma, 2012 .

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer

S. Verma, M. Milella, K. Pritchard, 2008, Cancer.

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!

S. Verma, 2008, Current oncology.

Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.

S. Verma, X. Zhu, X. Zhu, 2015, Current oncology.

S. Verma, D. Tripathy, D. Yardley, 2016, BMC Cancer.

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.

Liying Zhang, S. Verma, R. Chow, 2016, Annals of palliative medicine.

S. Verma, M. Campone, H. Burris, 2017 .

19PRibociclib + letrozole vs placebo + letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) and a high disease burden

S. Verma, M. Campone, J. Kattan, 2017 .

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

L. Fallowfield, G. Curigliano, S. Verma, 2013, The Lancet. Oncology.

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).

J. Bergh, L. Pusztai, C. Denkert, 2018 .

Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership

S. Verma, C. Simmons, J. Lemieux, 2020, The breast journal.

Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Michael C. Kolios, Michael C Kolios, Ali Sadeghi-Naini, 2013, Clinical Cancer Research.

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

F. André, S. Verma, C. Villarreal-Garza, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies

H. Iwata, E. Smit, C. Fuchs, 2021, Clinical Trials.

Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

R. Doebele, S. Verma, D. Camidge, 2015, Cancer.

Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age

S. Verma, C. Jackisch, 2011, Expert review of anticancer therapy.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

S. Verma, K. Pritchard, C. Kelly, 2010, The oncologist.

Measuring the quality of breast cancer care in women.

D. Moher, M. Sampson, S. Verma, 2004, Evidence report/technology assessment.

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.

J. Cuzick, A. Buzdar, R. Chlebowski, 2009, Breast.

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

C. V. D. van de Velde, S. Verma, K. Pritchard, 2010, Cancer treatment reviews.

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

J. Mackey, S. Verma, G. Batist, 2011, The oncologist.

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group

J. Mackey, M. Sawyer, S. Verma, 2008, Current oncology.

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study

Kelvin K. W. Chan, C. Earle, G. Tomlinson, 2016, Breast Cancer Research and Treatment.

Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome

S. Verma, J. Raphael, 2015, Breast Cancer Research and Treatment.

Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter

S. Verma, S. Gandhi, 2007, Breast Cancer Research and Treatment.

Validation of the long-term quality of life breast cancer scale (LTQOL-BC) by health care professionals

S. Verma, E. Rakovitch, E. Chow, 2015, Supportive Care in Cancer.

Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach

Gregory J. Czarnota, Ali Sadeghi-Naini, Lakshmanan Sannachi, 2016, Oncotarget.

A systematic review and quality appraisal of international guidelines for early breast cancer systemic therapy: Are recommendations sensitive to different global resources?

S. Verma, S. Alibhai, S. Gandhi, 2015, Breast.

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

L. Ek, S. Verma, P. Bendahl, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Early breast cancer in the older woman.

S. Verma, S. Gandhi, 2011, The oncologist.

Dose response in the treatment of breast cancer

S. Verma, M. Retsky, S. Tsai, 1994, The Lancet.

Adjuvant targeted therapy in early breast cancer

K. Gelmon, J. Mackey, J. Ragaz, 2009, Cancer.

Anthracyclines in early-stage breast cancer: is it the end of an era?

S. Verma, D. Robson, 2009, The oncologist.

92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

H. Iwata, C. Powell, S. Verma, 2021 .

J. Baselga, S. Verma, D. Miles, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

E. Winer, G. Hortobagyi, K. Blackwell, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.

J. Mackey, S. Verma, S. Damaraju, 2015 .

Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death

S. Verma, E. Rakovitch, G. Dranitsaris, 2005, Breast Cancer Research and Treatment.

Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.

H. Rugo, S. Verma, R. Finn, 2018 .

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

S. Verma, M. Campone, L. Hart, 2017, Breast Cancer Research and Treatment.

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, H. Iwata, Yeon-Hee Park, 2022, Cancer Research.

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

P. Fasching, G. Hortobagyi, S. Verma, 2019, Journal of Clinical Oncology.

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.

J. Baselga, T. Wilson, N. Harbeck, 2016 .

Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors

J. Baselga, T. Wilson, N. Harbeck, 2016 .

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer

S. Verma, P. Bedard, K. Towns, 2008, Current oncology.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

A. Rossi, S. Verma, G. Tonini, 2008 .

Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.

J. Blay, A. Lluch, S. Verma, 2009 .

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

A. Schneeweiss, Bing-he Xu, F. André, 2018 .

Abstract P3-12-04: A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer

S. Kesari, S. Verma, C. Anders, 2012 .

Patient adherence to aromatase inhibitor treatment in the adjuvant setting.

J. Bajcar, S. Verma, Y. Madarnas, 2011, Current oncology.

Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment

B. Manns, S. Verma, E. Spackman, 2018 .

291PPALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)

K. Gelmon, H. Rugo, N. Harbeck, 2017 .

Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).

E. Winer, G. Hortobagyi, K. Blackwell, 2017 .

Treatment and follow-up strategies in desmoid tumours: a practice guideline.

S. Verma, R. Kandel, X. Yao, 2014, Current oncology.

Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?

S. Verma, I. Quirt, B. Melosky, 2013, Critical reviews in oncology/hematology.

Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3.

M. Dowsett, S. Loi, H. Iwata, 2016 .

Importance of Literature in Pharmacovigilance: A Review

S. Verma, A. Gupta, Simranjeet Kaur, 2016 .

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

S. Loi, H. Iwata, S. Loibl, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Which pain intensity scale from the Brief Pain Inventory correlates most highly with functional interference scores in patients experiencing taxane-induced arthralgia and myalgia?

E. Stacey, Liying Zhang, S. Verma, 2016, Supportive Care in Cancer.

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer

J. Mackey, S. Verma, M. Clemons, 2009, Current oncology.

A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).

H. Iwata, M. Robson, Yeon-Hee Park, 2020 .

A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence.

S. Verma, N. Nixon, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

J. Baselga, T. Wilson, N. Harbeck, 2016 .

In the end what matters most? A review of clinical endpoints in advanced breast cancer.

J. Mackey, S. Verma, G. Batist, 2011, The oncologist.

Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Michael C. Kolios, M. Yaffe, S. Verma, 2013, Clinical Cancer Research.

Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.

B. Erikstein, S. Verma, D. Miles, 2001 .

Final Survival Analysis of ROSE/TRIO-012.

K. Gelmon, J. Mackey, S. Verma, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.

S. Verma, S. Gandhi, S. Giilck, 2013, Current oncology.

Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer.

S. Verma, C. Kelly, K. Pritchard, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

S. Loi, H. Iwata, F. André, 2017 .

breast cancer, locally advanced and metastaticFirst-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

E. Winer, G. Hortobagyi, K. Blackwell, 2016 .

317TiPIMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)

A. Schneeweiss, F. André, S. Verma, 2017 .